137 related articles for article (PubMed ID: 36084319)
1. Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo.
Martines C; Chakraborty S; Vujovikj M; Gobessi S; Vaisitti T; Deaglio S; Laurenti L; Dimovski AJ; Efremov DG
Blood; 2022 Dec; 140(22):2335-2347. PubMed ID: 36084319
[TBL] [Abstract][Full Text] [Related]
2. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM
Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085
[TBL] [Abstract][Full Text] [Related]
3. B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation.
Chakraborty S; Martines C; Porro F; Fortunati I; Bonato A; Dimishkovska M; Piazza S; Yadav BS; Innocenti I; Fazio R; Vaisitti T; Deaglio S; Zamò A; Dimovski AJ; Laurenti L; Efremov DG
Blood; 2021 Sep; 138(12):1053-1066. PubMed ID: 33900379
[TBL] [Abstract][Full Text] [Related]
4. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.
Suljagic M; Longo PG; Bennardo S; Perlas E; Leone G; Laurenti L; Efremov DG
Blood; 2010 Dec; 116(23):4894-905. PubMed ID: 20716772
[TBL] [Abstract][Full Text] [Related]
5. Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia.
Giménez N; Schulz R; Higashi M; Aymerich M; Villamor N; Delgado J; Juan M; López-Guerra M; Campo E; Rosich L; Seiffert M; Colomer D
Leukemia; 2020 Jan; 34(1):100-114. PubMed ID: 31197259
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis.
Delvecchio VS; Sana I; Mantione ME; Vilia MG; Ranghetti P; Rovida A; Angelillo P; Scarfò L; Ghia P; Muzio M
Br J Haematol; 2020 May; 189(3):475-488. PubMed ID: 32057093
[TBL] [Abstract][Full Text] [Related]
7. Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL.
Iacovelli S; Hug E; Bennardo S; Duehren-von Minden M; Gobessi S; Rinaldi A; Suljagic M; Bilbao D; Bolasco G; Eckl-Dorna J; Niederberger V; Autore F; Sica S; Laurenti L; Wang H; Cornall RJ; Clarke SH; Croce CM; Bertoni F; Jumaa H; Efremov DG
Blood; 2015 Mar; 125(10):1578-88. PubMed ID: 25564405
[TBL] [Abstract][Full Text] [Related]
8. TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.
Mongini PK; Gupta R; Boyle E; Nieto J; Lee H; Stein J; Bandovic J; Stankovic T; Barrientos J; Kolitz JE; Allen SL; Rai K; Chu CC; Chiorazzi N
J Immunol; 2015 Aug; 195(3):901-23. PubMed ID: 26136429
[TBL] [Abstract][Full Text] [Related]
9. B-cell antigen receptor expression and phosphatidylinositol 3-kinase signaling regulate genesis and maintenance of mouse chronic lymphocytic leukemia.
Schmid VK; Khadour A; Ahmed N; Brandl C; Nitschke L; Rajewsky K; Jumaa H; Hobeika E
Haematologica; 2022 Aug; 107(8):1796-1814. PubMed ID: 35021605
[TBL] [Abstract][Full Text] [Related]
10. Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity.
Alhakeem SS; McKenna MK; Oben KZ; Noothi SK; Rivas JR; Hildebrandt GC; Fleischman RA; Rangnekar VM; Muthusamy N; Bondada S
J Immunol; 2018 Jun; 200(12):4180-4189. PubMed ID: 29712773
[TBL] [Abstract][Full Text] [Related]
11. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.
Yan XJ; Albesiano E; Zanesi N; Yancopoulos S; Sawyer A; Romano E; Petlickovski A; Efremov DG; Croce CM; Chiorazzi N
Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11713-8. PubMed ID: 16864779
[TBL] [Abstract][Full Text] [Related]
12. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
Reiff SD; Mantel R; Smith LL; Greene JT; Muhowski EM; Fabian CA; Goettl VM; Tran M; Harrington BK; Rogers KA; Awan FT; Maddocks K; Andritsos L; Lehman AM; Sampath D; Lapalombella R; Eathiraj S; Abbadessa G; Schwartz B; Johnson AJ; Byrd JC; Woyach JA
Cancer Discov; 2018 Oct; 8(10):1300-1315. PubMed ID: 30093506
[TBL] [Abstract][Full Text] [Related]
13. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome.
Rossi D; Spina V; Cerri M; Rasi S; Deambrogi C; De Paoli L; Laurenti L; Maffei R; Forconi F; Bertoni F; Zucca E; Agostinelli C; Cabras A; Lucioni M; Martini M; Magni M; Deaglio S; Ladetto M; Nomdedeu JF; Besson C; Ramponi A; Canzonieri V; Paulli M; Marasca R; Larocca LM; Carbone A; Pileri SA; Gattei V; Gaidano G
Clin Cancer Res; 2009 Jul; 15(13):4415-22. PubMed ID: 19509140
[TBL] [Abstract][Full Text] [Related]
14. Richter syndrome in B-cell chronic lymphocytic leukemia.
Nakamura N; Abe M
Pathol Int; 2003 Apr; 53(4):195-203. PubMed ID: 12675762
[TBL] [Abstract][Full Text] [Related]
15. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model.
Shukla A; Cutucache CE; Sutton GL; Pitner MA; Rai K; Rai S; Opavsky R; Swanson PC; Joshi SS
Exp Hematol; 2016 Jan; 44(1):30-7.e1. PubMed ID: 26435347
[TBL] [Abstract][Full Text] [Related]
16. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
[TBL] [Abstract][Full Text] [Related]
17. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients.
Parikh SA; Rabe KG; Call TG; Zent CS; Habermann TM; Ding W; Leis JF; Schwager SM; Hanson CA; Macon WR; Kay NE; Slager SL; Shanafelt TD
Br J Haematol; 2013 Sep; 162(6):774-82. PubMed ID: 23841899
[TBL] [Abstract][Full Text] [Related]
18. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
19. Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy.
Jamroziak K; Tadmor T; Robak T; Polliack A
Leuk Lymphoma; 2015 Jul; 56(7):1949-58. PubMed ID: 25356923
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling.
De Nardo D; Balka KR; Cardona Gloria Y; Rao VR; Latz E; Masters SL
J Biol Chem; 2018 Sep; 293(39):15195-15207. PubMed ID: 30076215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
